Literature DB >> 12520583

Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy.

M Tanaka1, Y Kitajima, S Sato, K Miyazaki.   

Abstract

BACKGROUND: MUC1 mucin is known to be highly expressed in carcinomas that show invasive growth and poor prognosis. Impairment of adhesion molecule E-cadherin expression has been widely accepted as a critical event for cancer invasion and metastasis. The present study evaluated the combination of mucin and E-cadherin status as a possible predictor of patients suitable for minimally invasive therapy for gastric cancer.
METHODS: Two hundred and nine paraffin-embedded specimens of gastric carcinoma (141 early, 68 advanced) were examined by immunohistochemical staining using monoclonal antibodies against MUC1 mucin (MUC-1-CORE, DF3), MUC2 mucin (Ccp58) and E-cadherin (anti-E-cad).
RESULTS: Gastric carcinoma with MUC1-positive expression demonstrated malignant characteristics. Normal E-cadherin expression showed an inverse correlation with MUC1 expression. Patients with early gastric carcinoma who had a combination of normal E-cadherin and MUC1-negative expression had no recurrence and a favourable prognosis. Moreover, cancers with normal E-cadherin/MUC1-negative expression were not found at an advanced stage in differentiated-type carcinoma.
CONCLUSION: A normal E-cadherin/MUC1-negative expression pattern in gastric cancer is a favourable marker. Preoperative estimation of the E-cadherin and MUC1 status of an endoscopic biopsy specimen may help select appropriate patients for minimally invasive treatment of gastric cancer. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons Ltd

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520583     DOI: 10.1002/bjs.4014

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

1.  Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.

Authors:  Lindsey Ulkus Rodrigues; Leah Rider; Cera Nieto; Lina Romero; Anis Karimpour-Fard; Massimo Loda; M Scott Lucia; Min Wu; Lihong Shi; Adela Cimic; S Joseph Sirintrapun; Rosalie Nolley; Colton Pac; Haitao Chen; Donna M Peehl; Jianfeng Xu; Wennuan Liu; James C Costello; Scott D Cramer
Journal:  Cancer Res       Date:  2015-03-15       Impact factor: 12.701

2.  Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma.

Authors:  Edaise M Silva; Maria D Begnami; José Humberto T G Fregnani; Adriane G Pelosof; Claudia Zitron; André L Montagnini; Fernando Augusto Soares
Journal:  Gastric Cancer       Date:  2008-09-30       Impact factor: 7.370

3.  Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance.

Authors:  Hong-Kai Zhang; Qiu-Min Zhang; Tie-Hua Zhao; Yuan-Yuan Li; Yong-Fen Yi
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

4.  Elevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.

Authors:  Yue Yang; Huijuan Zhang; Mingyan Zhang; Qingwei Meng; Li Cai; Qingyuan Zhang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

5.  MUC2 Expression Is Correlated with Tumor Differentiation and Inhibits Tumor Invasion in Gastric Carcinomas: A Systematic Review and Meta-analysis.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Guhyun Kang; Dong-Hoon Kim; Kyungeun Kim; In-Gu Do; Dong Hyun Kim
Journal:  J Pathol Transl Med       Date:  2015-05-15

6.  Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer.

Authors:  S Senapati; P Chaturvedi; P Sharma; G Venkatraman; J L Meza; W El-Rifai; H K Roy; S K Batra
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

7.  Mucin 1 gene (MUC1) and gastric-cancer susceptibility.

Authors:  Norihisa Saeki; Hiromi Sakamoto; Teruhiko Yoshida
Journal:  Int J Mol Sci       Date:  2014-05-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.